EC Number |
Application |
Reference |
---|
1.14.11.51 | analysis |
development of assay method using a methylation-sensitive restriction endonuclease |
764135 |
1.14.11.51 | medicine |
ALKBH1 overexpression decreases hepatocellular carcinoma cell viability, induces apoptosis, and decreases migration and invasion. 23779 gain-of-6 mA regions and 11240 loss-of-6 mA regions are differentially identified in hepatocellular carcinoma tissues. The differential gain and loss of 6 mA regions are considerably enriched in intergenic regions. 7% of the differential 6 mA modifications are associated with tumors, with 60 associated with oncogenes and 57 with tumor suppressor genes, and 17 are common to oncogenes and TSGs |
764811 |
1.14.11.51 | medicine |
during the progression of vascular calcification in a model of chronic kidney disease, increased ALKBH1 expression is linked to decreased 6mA levels |
765144 |
1.14.11.51 | medicine |
expression levels of ALKBH1 in lung cancer tissues and cells are up regulated. The invasion and migration abilities of lung cancer cells are significantly suppressed in vitro upon the silencing of ALKBH1 while they are significantly promoted upon its overexpression |
764114 |
1.14.11.51 | medicine |
in patients with chronic kidney disease, leukocyte 6mA levels are significantly reduced as the severity of vascular calcification increases. Decreased 6mA demethylation results from the upregulation of ALKBH1. ALKBH1 overexpression aggravates whereas its depletion blunts vascular calcification progression and osteogenic reprogramming in vivo and in vitro |
765144 |